Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7

Williams, J.Andrew, Ring, Barbara J., Cantrell, Varon E., Jones, David R., Eckstein, James, Ruterbories, Kenneth, Hamman, Mitchell A., Hall, Stephen D. +1 more·2002·Drug Metabolism and Disposition
DOI 10.1124/dmd.30.8.883

Cited by (472)

Items 401–472 of 472

  1. Pharmacokinetics in Pregnancy
    Gregory J. Anger, Micheline Piquette‐Miller · 2017 · Elsevier eBooks
  2. Effect of (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats
    Eun-A Ryu, Su-Jin Kang, Chang‐Hyun Song, Bong-Hyo Lee, Seong-Hun Choi, Chang-Hyun Han, Young Joon Lee, Sae‐Kwang Ku · 2017 · 대한한의학회지
  3. Effects of mixed formulation of tamoxifen and blue honeysuckle on the pharmacokinetics profiles of tamoxifen after single oral administration
    Jin-Ryul Hu, Tae-Woo Jang, Su-Jin Kang, Sae‐Kwang Ku, Seong-Hun Choi, Young Joon Lee · 2019 · 대한한의학회지
  4. Clinical pharmacogenetics
    Anuradha Ramamoorthy, Tristan M. Sissung, Michael A. Pacanowski · 2021 · Elsevier eBooks
  5. Comparison of the CYP3A Selective Inhibitors CYP3cide, Clobetasol, and Azamulin for Their Potential to Distinguish CYP3A7 Activity in the Presence of CYP3A4/5
    Hannah M. Work, Sylvie E. Kandel, Jed Noah Lampe · 2024 · Drug Metabolism and Disposition
  6. The importance of the toxicological analysis in newborns: Clearing the case of a tetralogy of Fallot with a paradoxical reaction to 1-hydroxymidazolam
    Cristiano Ialongo, Marco Marano, Pierfrancesco Bertucci, Lt Marsella, Andrea De Zorzi, Sergio Bernardini · 2016 · Journal of pediatric and neonatal individualized medicine
  7. Biomedical literature mining for pharmacokinetics numerical parameter collection
    Luis Mateus Rocha, Zhiping Paul Wang · 2013
  8. Pharmacokinetics in pregnancy
    Gregory J. Anger, Wanying Dai, Micheline Piquette‐Miller · 2022 · Elsevier eBooks
  9. Study on herb-drug interactions
    Liu L. Yang · 2011 · RMIT Research Repository (RMIT University Library)
  10. Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes
    Vita Dolžan · 2012 · Wiley eBooks
  11. The role of CYP3A4/5 in alprazolam metabolism
    Annika Allqvist · 2010 · Figshare
  12. Effects of Selected Natural Health Products on Drug Metabolism: Implications for Pharmacovigilance
    Rui Liu · 2011 · Library and Archives Canada (Government of Canada)
  13. Authors’ Reply to Völler et al: “Comment on: Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II”
    Khaled Abduljalil, Xian Pan, Amita Pansari, Masoud Jamei, Trevor N. Johnson · 2021 · Clinical Pharmacokinetics
  14. Interindividual Variability in the Cytochrome P450 3A4 Drug Metabolizing Enzyme: Effect of the CYP3A4*1G Genetic Variant
    Kasse Skagen · 2014 · The Mathematics Enthusiast
  15. Survenue de délirium et/ou coma iatrogénique aux soins intensifs : évaluation de facteurs pouvant influencer le devenir et la toxicité du fentanyl et/ou du midazolam
    Vadym Tarasevych · 2010
  16. Do Cytochrome P450 Enzymes Contribute to the Metabolism of Xenobiotics in Human?
    Khaled M. Abass, Petri Reponen, Miia Turpeinen, Sampo Mattila, Olavi Pelkone · 2010 · InTech eBooks
  17. Efeitos de hipolipemiantes sobre a expressão de CYP3A4 e CYP3A5 in vitro e in vivo
    Maria Alice V. Willrich · 2011
  18. Estudo da expressão gênica e de polimorfismos da CYP3A5 em pacientes com hipercolesterolemia tratados com atorvastatina
    Maria Alice V. Willrich · 2006
  19. An investigation of Cytochrome P450 function in human cell Lines for potential use in a bioartificial liver device
    Amy Thomas · 2010 · UCL Discovery (University College London)
  20. Characteristics of cytochrome P450-catalysed drug metabolism with focus on a black Tanzanian population
    Agneta Wennerholm · 2003 · Figshare
  21. A novel simultaneous modeling approach to estimate linearity of pharmacokinetic parameters, including saturation of intestinal efflux, in the rat
    J. Andrew Williams, Vaishali Sahasrabudhe, Justin Walton, Tong Zhu, Gary Hudson, Jeffrey R. Koup · 2005 · Journal of Pharmacological and Toxicological Methods
  22. Análise de genes moduladores do fenótipo da forma não clássica da deficiência da 21-hidroxilase
    Vivian O Moura · 2011 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  23. HEPATIC DRUG METABOLISM
    Weili Huang, Yvonne S. Lin, Donavon J. McConn, Justina C. Calamia, Rheem A. Totah, Nina Isoherranen, Mary Glodowski, Kenneth E. Thummel · 2004
  24. Nao TORIMOTO, Itsuko ISHII, Ken-ichi TOYAMA, Masayuki HATA, Kanako
    Hitoshi Shimomura, Hiroyoshi Nakamura, Noritaka Ariyoshi, Shigeru Ohmori, Mitsukazu Kitada · 2006
  25. Cyclosporin A som hemmer av CYP3A4 og CYP3A5
    Ingrid Kristine Ohm · 2010 · NORA - Norwegian Open Research Archives
  26. Physiologic effects of cytochrome P450 3A activity
    Raymond C. Givens · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  27. Effect of Cytochrome P450 2D6 and 3A Enzyme Inhibition on the Metabolism of Oxycodone
    Juha Grönlund · 2011 · UTUPub (University of Turku)
  28. CYP3A-fenotype, målt som 4β-hydroksykolesterol, hos pasienter før og etter nyretransplantasjon
    Ane Olastuen · 2015 · NORA - Norwegian Open Research Archives
  29. Cobicistat and Ritonavir as Pharmacoenhancers for Antiviral Drugs
    Lianhong Xu, Manoj C. Desai · 2013 · Royal Society of Chemistry eBooks
  30. Mining Biomedical Literature to Extract Pharmacokinetic Drug-Drug Interactions
    Shreyas Karnik · 2014 · IUScholarWorks (Indiana University)
  31. Farmakokinetisk betydning av sekvensvarianter i CYP3A4, CYP3A5, POR og PPARA
    Miriam Dahl · 2013 · NORA - Norwegian Open Research Archives
  32. Drug Interactions with St. John's Wort and Echinacea
    Jude Christopher Gorski · 2006 · Drugs and the pharmaceutical sciences
  33. Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
    Jennifer Ann Lowry, James Steven Leeder · 2012 · Cambridge University Press eBooks
  34. Expression of Cytochrome P450 in Human Fetus : Focused on CYP3As in Liver
    Tamihide Matsunaga, Masataka Maruyama, Shigeru Ohmori · 2008 · 信州医学雑誌
  35. Role of pharmacogenetics for the improvement of cancer treatment
    Vita Dolžan, Petra Bohanec Grabar, Cristina Rodríguez‐Antona · 2007 · DOAJ (DOAJ: Directory of Open Access Journals)
  36. Effects of gemfibrozil and rifampicin on the pharmacokinetics of HMG-CoA reductase inhibitors
    Carl Kyrklund · 2004 · Työväentutkimus Vuosikirja
  37. Maturation of Cytochrome P450 3A Mediated Drug Metabolism
    Catherijne A. J. Knibbe, Dick Tibboel, Saskia N. de Wildt, Ibrahim Ince · 2008
  38. ASSESSED IN VITRO USING A CYP3A4 SELECTIVE INACTIVATOR (CYP3CIDE)
    Elaine Tseng, Robert L. Walsky, Ricardo A. Luzetti, Jennifer J. Harris, Rachel E. Kosa, Theunis C. Goosen, Michael A. Zientek, Ronald Scott Obach · 2014
  39. Hypotension Harry
    Matthew E Hart, Bryan J. Read, Wayne T. Nicholson, Toby N. Weingarten · 2015 · Springer eBooks
  40. Impact of CYP3A5 Genetic Polymorphism on the Biotransformation of Drugs and Environmental Toxins
    Landry K. Kamdem · 2006 · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG))
  41. Abundant migration of midazolam and 1’-hydroxymidazolam into the fetal brain following midazolam administration to pregnant mice in the second trimester
    Satoshi Kitaoka, Jo Hatogai, Nanako Niikura, Miho Hirata, Nanako Fukasawa, Satoru Miyazaki, Naoto Yamaguchi, Shohei Harada, Masanaho Sasatsu, Kiyoshi Sugiyama et al. · 2018 · Fundamental Toxicological Sciences
  42. Drug–Drug Interactions as a Complication of Maxillofacial Surgery
    James J. Omlie, Andrew Herlich · 2017 · Springer eBooks
  43. Genomics and Drug-Metabolizing Enzymes and Its Application in Drug Delivery: Evaluating the Influence of the Microbiome
    Sheeba Varghese Gupta · 2018 · Springer eBooks
  44. Consequences of Antiepileptic Drug Exposure During Postnatal Liver Development on Cytochrome P450 Expression and Metabolism
    Stephanie C. Piekos · 2018 · OpenCommons at University of Connecticut (University of Connecticut)
  45. A proposed simple screening method to determine relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro
    Jun Matsumoto, Hiroyoshi Nakamura, Su Nwe San, Hikari Sato, Manami Takezawa, Ryuto Kishi, Yutaro Kito, Junko Sugano, Mai Izuki, Nao Yanagisawa et al. · 2019 · Personalized Medicine Universe
  46. Regulation of P-glycoprotein and ABCP transporters
    Dhanashri Kolwankar · 2003
  47. Introduction to Human Cytochrome P450 Superfamily
    Shufeng Zhou · 2018 · CRC Press eBooks
  48. Bedeutung erblicher Faktoren für die Variabilität der Pharmakokinetik von Arzneimitteln im Vergleich zwischen oraler und intravenöser Dosierung anhand einer Zwillingsstudie
    Becker, Stefanie · 2020
  49. [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].
    Ying He, Xiu-Mei Zao, Xuehua Wei · 2018 · Europe PMC (PubMed Central)
  50. Effect of phyllanthus amarus schum. & thonn. extract on the pharmacokinetics of midazolam in rabbits
    Putthaporn Kaewmeesri · 2013
  51. Biochemical mechanisms of drug toxicity
    Jack Uetrecht, Denis M. Grant, Peter G. Wells · 2021 · Elsevier eBooks
  52. RETRACTED: Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells in vitro
    Hong-yan Song, Jing-sheng Xia, Yonggang Chen, Ling Chen · 2021 · Human & Experimental Toxicology · Retracted
  53. Environmental and Endogenous Factors Determining the Expression of Toxicity
    2009 · Wiley eBooks
  54. Introduction to Human Cytochrome P450 Superfamily
    2016 · CRC Press eBooks
  55. Characterisation of inducible proteins in the HepG2 cell line proteome
    Ellero, Andrea Antonio · 2022 · UpSpace Institutional Repository (University of Pretoria)
  56. RECEPTOROWE MECHANIZMY REGULACJI METABOLIZMU KWASÓW ŻÓŁCIOWYCH I KSENOBIOTYKÓW. ZNACZENIE EKSPRESJI CYP3A4 DLA BEZPIECZEŃSTWA I SKUTECZNOŚCI FARMAKOTERAPII
    Grażyna Kubiak-Tomaszewska, JAN PACHECKA, Jacek Łukaszkiewicz, Piotr Tomaszewski · 2016 · Prospects in Pharmaceutical Sciences
  57. Variations in the Frequencies of Polymorphisms in the CYP450s Genes in Eight Major Ethnicities of Iran: A Review of the Human Data
    Navid Neyshaburinezhad, Hengameh Ghasim, Mohammad Reza Rouini, Youssef Daali, Yalda H. Ardakani · 2022 · Journal of Personalized Medicine
  58. EGFR TKI PET/CT in advanced stage non-small cell lung cancer patients
    Eveline Annette van de Stadt · 2023
  59. Cytochrome P450 (inhibitors for the metabolism of drugs)
    Atilla Akdemir · 2023 · Elsevier eBooks
  60. Investigating the mechanism of Banxia Xiexin Decoction in treating Helicobacter pylori-associated chronic atrophic gastritis through network pharmacology and molecular docking
    Chen Gao, Xiaoqian Zhang, Yao Ma, Hong Chang, Songli Shi, Fengli Gao · 2024 · Journal of Radiation Research and Applied Sciences
  61. CYP3A5 inhibition causes G1/S blockade and synergizes with CDK4/6 inhibitor to suppress prostate cancer cell growth: Implications in reducing health disparity
    Jeetesh Sharma, Imran K. Mohammed, Richard L. Tillett, Jake McLean, Shirley Shen, Ajay P. Singh, Oscar B. Goodman, Edwin C. T. Oh, Ranjana Mitra · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  62. Construction of physiologically based pharmacokinetic model to predict CYP1A autoinduction by multi-kinase inhibitor TSU-68 based on in vitro induction kinetics
    Yasuhiro Ohno, Kunihiro Yoshisue, Yusuke Masuo, Yukio Kato · 2025 · Journal of Pharmaceutical Sciences
  63. Breathing new life into sensitized patients
    2025 · Frontiers Media SA eBooks
  64. Pharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions
    Arzu Gunes · 2008 · Uppsala University Publications (Uppsala University)
  65. Expanding the Genetic Landscape of Craniofacial Anomalies Through Transcriptome-Wide Association Studies
    Elly Brokamp, Alexandra Scalici, Tyne W. Miller‐Fleming, David Bin‐Chia Wu, Wendy K. Chung, Monica Hsiung Wojcik, Nancy Jean Cox, Megan M. Shuey · 2025 · Research Square
  66. Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach
    Autumn M. McKnite, Abdullah Hamadeh, John Porter Hunt, Danielle J. Green, Carina E. Imburgia, Aviva Whelan, Rachel E. Hudson, Andrew Chevalier, Cheryl L. Mathis, Michelle J. Yang et al. · 2026 · CPT Pharmacometrics & Systems Pharmacology
  67. A CYP3A7 metabolically competent human induced pluripotent stem cell-derived hepatocyte-like cell (hHLC3A7) model for drug safety assessment in the newborn
    Emily G. Gracey, Sylvie E. Kandel, Jed Noah Lampe · 2026 · Drug Metabolism and Disposition
  68. Hydramethylnon induces synergistic toxicity of pyrethroid mixtures in human lung epithelial cells
    Hye‐Jin Jeong, Hye-In Park, Ju-Hui Im, Ju-Hui Im, Seung Min Choi, Chang‐Ik Choi, Myungwon Seo, Yong Joo Park · 2026 · Toxicological Research
  69. Antenatal hypoxia and dexamethasone independently alter hepatic cytochrome P450 activity and glucocorticoid receptor isoform cellular localisation in ovine offspring
    Millicent G.A. Bennett, Ashley S. Meakin, Kimberley J. Botting, Youguo Niu, Sage G. Ford, Michael D. Wiese, Dino A. Giussani, Janna Leigh Morrison · 2026 · Pharmacological Research
  70. Rational design of a fluorescent probe for selective sensing of human cytochrome P450 2C19 and its application in exploration of enzymatic inactivation
    Zhenhao Tian, Fei Yan, Yichao Su, Xiaoren Zhang, Jiayue Wang, Jianing Xiao, Yifei Dang, Jing Ning, Lei Feng, Chengjuan Xing et al. · 2026 · Biosensors and Bioelectronics
  71. CYP3A and CYP2D6 variability in antimalarial pharmacokinetics and pharmacogenetics across populations: a narrative review
    Ursula Benz, Amy Junnila, Günter C. Müller, Patricia Schlagenhauf, Camilla Rothe, Markus Schwarz · 2026 · Malaria Journal
  72. Relationships of genetic polymorphisms in CYP3A5 and UGT1A1 with plasma bictegravir concentrations and subjective adverse symptoms in Japanese patients with HIV-1 infection
    Hiroki Yagura, Ayumi Hisari, Takao Nakauchi, Ayano Fujiwara, Kazuyuki Hirota, Takashi Ueji, Yasuharu Nishida, Tomoko Uehira, Takuma Shirasaka, Jun A. Komano et al. · 2026 · Journal of Antimicrobial Chemotherapy